非关节疼痛与患者整体评估在类风湿关节炎启用新DMARD前后的关系
研究纳入197例开始新DMARD的活动性RA患者,评估非关节疼痛(NAP)与患者整体评估(PtGA)的关联及疼痛强度的中介作用。基线时每增加1个NAP部位与PtGA升高0.20分相关(95%CI 0.12-0.28),疼痛强度中介了61.8%的关联;3个月时结果相似。
要点
- 活动性RA患者中NAP常见,基线报告率92.9%,3个月时84.8%。
- NAP部位数与PtGA呈线性正相关,基线β=0.20(95%CI 0.12-0.28)。
- 疼痛强度中介了NAP与PtGA关联的61.8%,3个月时结果相似。
核心结论
- NAP与PtGA存在显著线性关系,且大部分可由疼痛强度解释。
- 研究提示NAP增加RA患者感知健康状态负担,可能影响治疗决策。
研究设计与样本
- 纳入197例开始新DMARD的活动性RA成人患者,平均年龄55.1岁(SD 14.4),平均病程10.6年(SD 12.6),平均CDAI 23.9(SD 14.6)。
- 采用身体疼痛图评估NAP(0-19个部位),并完成PtGA和疼痛强度评估。
- 使用调整多变量线性回归评估NAP与PtGA关联,并用线性回归模型分别基线及3个月进行中介分析,所有模型调整潜在混杂因素。
主要发现
- 基线NAP报告率92.9%,3个月时84.8%。
- 基线时每1个NAP部位与PtGA高0.20分相关(β=0.20,95%CI 0.12-0.28)。
- 基线时疼痛强度中介了61.8%的NAP与PtGA关联,3个月时观察到相似结果。
临床怎么用
- 临床评估RA疾病活动度时应关注NAP,避免因非关节疼痛导致PtGA升高而误判疾病活动。
- 针对不同疼痛类型进行特异性治疗,可能减少不必要的DMARD更换。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Nonarticular pain (NAP) may contribute to patient global assessment (PtGA), confound disease activity assessment, and influence treatment decisions. Our aims were to (1) evaluate the association between NAP and PtGA in adults with active rheumatoid arthritis (RA) starting a new disease-modifying antirheumatic drug (DMARD) and (2) determine the extent to which this relationship is mediated by pain intensity. METHODS: We enrolled adults with active RA initiating a new DMARD. Participants indicated NAP on a body pain diagram (0-19 sites) and completed assessments of PtGA and pain intensity. To evaluate the association between NAP and PtGA, adjusted multivariable linear regression was performed. Mediation analyses using linear regression models examined whether this association was mediated by pain intensity at baseline and at three months separately. All models were adjusted for potential confounders. RESULTS: The 197 participants were mostly female (83.8%), with a mean age of 55.1 (SD 14.4) years, a mean disease duration of 10.6 (SD 12.6) years, and a mean Clinical Disease Activity Index score of 23.9 (SD 14.6). NAP was reported by 92.9% at baseline and by 84.8% at three months. At baseline, each site of NAP (0-19) was associated with a 0.20-point higher PtGA (β = 0.20, 95% confidence interval 0.12-0.28). Pain intensity mediated 61.8% of this association. Similar findings were observed at three months. CONCLUSION: There was a significant linear relationship between NAP and PtGA, most of which could be explained by pain intensity. These findings raise awareness of NAP and its added burden of worse perceived health status in RA. This may help prevent unnecessary DMARD treatment changes and increase specificity in treatment of different pain types.
引用
- Meng C, Song J, Muhammad LN, et al. The Painful Truth: The Relationship Between Nonarticular Pain and Patient Global Assessment Before and After Initiating a New Disease-Modifying Antirheumatic Drug for Active Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2026. PMID: 42080629. doi:10.1002/acr.80081
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。